Acadian Asset Management LLC Purchases 1,606,802 Shares of Zentalis Pharmaceuticals, Inc. $ZNTL

Key Points

• Acadian Asset Management LLC has significantly increased its stake in Zentalis Pharmaceuticals by 150.6%, holding approximately 2.67 million shares worth about $4.24 million as of the latest SEC filing.
• Several other institutional investors, including Millennium Management LLC and GSA Capital Partners LLP, have also boosted their positions in Zentalis, reflecting growing interest in the company's stock.
• Zentalis Pharmaceuticals has a current market capitalization of $107.49 million and reported a quarterly loss of ($0.37) EPS, surpassing analysts' expectations for a larger loss.

Acadian Asset Management LLC raised its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 150.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,674,035 shares of the company's stock after buying an additional 1,606,802 shares during the period. Acadian Asset Management LLC owned about 3.72% of Zentalis Pharmaceuticals worth $4,244,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Captrust Financial Advisors bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $33,000. Cerity Partners LLC lifted its stake in shares of Zentalis Pharmaceuticals by 58.7% in the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock valued at $33,000 after purchasing an additional 7,579 shares during the period. Vident Advisory LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $45,000. Alpine Global Management LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 1st quarter valued at about $48,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $52,000.

Wall Street Analyst Weigh In

ZNTL has been the topic of a number of recent analyst reports. HC Wainwright raised Zentalis Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 7th. Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 7th. Finally, Wall Street Zen raised Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $5.84.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL traded up $0.03 during trading hours on Friday, reaching $1.52. The stock had a trading volume of 1,070,934 shares, compared to its average volume of 618,691. The stock has a 50 day simple moving average of $1.54 and a 200 day simple moving average of $1.45. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.01 and a 12-month high of $4.44. The stock has a market cap of $109.65 million, a P/E ratio of -0.67 and a beta of 1.76.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.19. On average, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.